Thorvardur Halfdanarson, MD
Medical Oncology · Rochester, MNNPI 1083684187
Payments from drug & device makers
Across 254 payments — averaging $12,923 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1.4M
- Brahms GmbH$685K
- Amgen$367K
- Array Biopharma Inc$186K
- Advanced Accelerator Applications$164K
- Novartis$164K
- plus $279K from 15 others
Across 5 payments — averaging $2297.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$9K
- Novartis Pharma AG$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 5 | $1,437,892 |
| Brahms GmbH | 86 | $685,116 |
| Amgen | 2 | $366,631 |
| Array Biopharma Inc | 13 | $185,978 |
| Advanced Accelerator Applications | 6 | $163,914 |
| Novartis | 5 | $163,600 |
| Servier Bioinnovation | 1 | $158,433 |
| Boehringer Ingelheim | 4 | $37,110 |
| Exelixis Inc. | 19 | $18,084 |
| Sanofi | 4 | $16,790 |
| Terumo Medical Corporation | 5 | $16,300 |
| Curium US LLC | 17 | $9,684 |
| Agios Pharmaceuticals, Inc. | 4 | $7,920 |
| Tersera Therapeutics LLC | 5 | $7,561 |
| Boehringer Ingelheim International GmbH | 3 | $2,905 |
| Lexicon Pharmaceuticals, Inc. | 4 | $1,712 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 12 | $1,629 |
| Fisher Scientific Company L.L.C. | 54 | $762 |
| Ipsen Biopharmaceuticals, Inc | 3 | $348 |
| Genentech USA, Inc. | 1 | $125 |
| AstraZeneca | 1 | $72 |
How this compares
$3,282,564 in reported general payments places this provider in the 85th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Rochester
- Evanthia GalanisRochester$72.3M
- Frank SinicropeRochester$10.3M
- Harry YoonRochester$10.2M
- Konstantinos LeventakosRochester$9.6M
- Matthew BlockRochester$8.1M
- Keith BibleRochester$7.5M
- Jian CampianRochester$7.3M
- Katharine PriceRochester$7M
- Robert McWilliamsRochester$6.3M
- Elisabeth HeathRochester$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.